Correction [0.03%]
纠正
Published Erratum
Neurodegenerative disease management. 2025 Feb 20:1. DOI:10.1080/17582024.2025.2468543 2025
Economic evaluation of mHealth solutions in PD: where do we stand? [0.03%]
mHealth在PD中经济评价：我们处于什么位置？
Foivos S Kanellos,Ermioni Petkou,Spyridon Konitsiotis et al.
Foivos S Kanellos et al.
Muhammad Shaheer Bin Faheem,Ahmed Ali Khan,Maheen Nawaz
Muhammad Shaheer Bin Faheem
A plain language summary of a study exploring the experiences of people with relapsing-remitting multiple sclerosis: what symptoms and impacts of the disease matter most and how can they be evaluated better? [0.03%]
有关探究复发型多发性硬化症患者的经历的研究摘要：哪些症状和疾病影响最重要，如何才能更好地评估它们？
Amy Barrett,Oyebimpe Olayinka-Amao,Tjalf Ziemssen et al.
Amy Barrett et al.
Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice [0.03%]
奥法木单抗临床应用的有效性、持久性、耐受性和安全性分析
Moein Amin,Tucker Harvey,Dan Michael Pineda et al.
Moein Amin et al.
Aims: To describe the 12-month effectiveness, persistence, tolerability, and safety of ofatumumab (OMB), a highly effective disease-modifying therapy (DMT) for relapsing multiple sclerosis (MS), in a real-world MS populat...
Friedreich ataxia: what can we learn from non-GAA repeat mutations? [0.03%]
弗里德赖希共济失调症：非GAA重复序列突变能告诉我们什么？
David R Lynch,M Shen,Robert B Wilson
David R Lynch
Friedreich ataxia (FRDA) is a slowly progressive neurological disease resulting from decreased levels of the protein frataxin, a small mitochondrial protein that facilitates the synthesis of iron-sulfur clusters in the mitochondrion. It is ...
Effects and mechanisms of computerized cognitive training in Huntington's disease: protocol for a pilot study [0.03%]
计算机认知训练在亨廷顿病中的效果和机制：一项概念验证研究方案
Katharine Huynh,Sharna Jamadar,Julie Stout et al.
Katharine Huynh et al.
Huntington's disease (HD) causes progressive cognitive decline, with no available treatments. Computerized cognitive training (CCT) has shown efficacy in other populations, but its effects in HD are largely unknown. This pilot study will ex...
Improvements in quality of life of people with relapsing multiple sclerosis treated with cladribine tablets during the 2-year CLARIFY-MS study: a plain language summary [0.03%]
克拉拉利夫御研之多发性硬化复发患者品质生活的改善：简易总结
Bruno Brochet,Alessandra Solari,Jeannette Lechner-Scott et al.
Bruno Brochet et al.
Biological activities of astaxanthin in the treatment of neurodegenerative diseases [0.03%]
虾青素治疗神经退行性疾病的作用机制及生物活性研究进展
Alireza Lotfi,Zahra Abroodi,Mozafar Khazaei
Alireza Lotfi
Introduction: Neurodegenerative diseases (NDs) develop with the gradual advancement of neuronal damage and dysfunction in the central nervous system (CNS). These disorders are mostly the outcomes of the improper sedimenta...
Effectiveness of neuro-feedback on Alzheimer's rehabilitation: a bibliometric analysis [0.03%]
基于文献计量的神经反馈用于阿尔茨海默病康复的有效性分析
Shruti Verma,Aditya Kurdekar
Shruti Verma
Background: Alzheimer's Disease (AD) is a neurodegenerative disorder with limited treatment options. Neurofeedback, a technique that trains brainwaves, has shown promise in addressing cognitive impairments. ...